Skip to main content

Table 3 Incidences of primary effectiveness outcomes in patients receiving THA

From: Venous thromboembolism after total joint arthroplasty: results from a Japanese multicenter cohort study

  Fondaparinux Enoxaparin UFH Others Medication (-) Total
n = 261 (%) n = 148 (%) n = 32 (%) n = 44 (%) n = 383 (%) n = 868 (%)
All venous thromboembolism 17 (6.5) 17 (11.5) 5 (15.6) 8 (18.2) 62 (16.2) 109 (12.6)
  Any DVT (up to POD10 ) 17 (6.5) 17 (11.5) 5 (15.6) 8 (18.2) 62 (16.2) 109 (12.6)
  Symptomatic DVT 0 1 (0.7) 0 0 1 (0.3) 2 (0.2)
   Distal 0 1 (0.7) 0 0 1 (0.3) 2 (0.2)
   Proximal 0 0 0 0 0 0
  Non-symptomatic DVT 17 (6.5) 16 (10.8) 5 (15.6) 8 (18.2) 61 (15.9) 107 (12.3)
   Distal 15 (5.7) 13 (8.8) 3 (9.4) 8 (18.2) 51 (13.3) 90 (10.4)
   Proximal 2 (0.8) 3 (2.0) 2 (6.3) 0 10 (2.6) 17 (2.0)
  PE (up to POD28) 0 0 0 0 0 0
  1. CI, confidence interval; DVT, deep vein thrombosis; PE, pulmonary embolism; POD, post-operative day; THA, total hip arthroplasty; UFH, unfractionated heparin.